Oxford BioMedica plc (OXB.L)
| Previous close | 503.00 |
| Open | 506.94 |
| Bid | 502.00 x 0 |
| Ask | 505.00 x 0 |
| Day's range | 494.91 - 529.66 |
| 52-week range | 414.00 - 1,678.00 |
| Volume | |
| Avg. volume | 156,617 |
| Market cap | 480.406M |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | 21.74 |
| EPS (TTM) | 0.23 |
| Earnings date | 20 Sept 2022 - 26 Sept 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,224.57 |
- Globe Newswire
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology. As part of the project, Oxford Biomedica’s LentiStable™ technology platform will be used to develop a producer cell line capab
- Globe Newswire
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with an undisclosed US-based private biotechnology company advancing a new generation of adoptive cell therapies. The LSA grants the new partner a non-exclusive licence to uti
- Simply Wall St.
Oxford Biomedica plc's (LON:OXB) Intrinsic Value Is Potentially 20% Below Its Share Price
How far off is Oxford Biomedica plc ( LON:OXB ) from its intrinsic value? Using the most recent financial data, we'll...
